Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Dec. 31, 2018	Feb. 01, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Consumer Healthcare Inc.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		51,798,384
Entity Emerging Growth Company	false
Entity Small Business	false

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Revenues
Total revenues	$ 241,414	$ 270,615	$ 734,751	$ 785,214
Cost of Sales
Cost of sales excluding depreciation	100,997	121,730	313,713	346,067
Cost of sales depreciation	1,182	1,211	3,708	3,899
Cost of sales	102,179	122,941	317,421	349,966
Gross profit	139,235	147,674	417,330	435,248
Operating Expenses
Advertising and promotion	34,504	35,835	108,657	111,967
General and administrative	20,485	20,820	68,460	63,229
Depreciation and amortization	6,705	7,129	20,545	21,482
Gain on divestiture	0	0	(1,284)	0
Total operating expenses	61,694	63,784	196,378	196,678
Operating income	77,541	83,890	220,952	238,570
Other (income) expense
Interest income	(39)	(119)	(172)	(273)
Interest expense	26,366	25,983	79,509	79,314
Other expense (income), net	218	387	640	(119)
Total other expense	26,545	26,251	79,977	78,922
Income before income taxes	50,996	57,639	140,975	159,648
Provision (benefit) for income taxes	12,829	(257,154)	37,501	(219,609)
Net income	$ 38,167	$ 314,793	$ 103,474	$ 379,257
Earnings per share:
Basic (in USD per share)	$ 0.74	$ 5.93	$ 1.99	$ 7.14
Diluted (in USD per share)	$ 0.73	$ 5.88	$ 1.97	$ 7.08
Weighted average shares outstanding:
Basic (in shares)	51,881	53,129	52,119	53,089
Diluted (in shares)	52,202	53,543	52,431	53,531
Comprehensive income, net of tax:
Currency translation adjustments	$ (2,020)	$ 4,492	$ (7,139)	$ 8,327
Unrecognized net gain on pension plans	0	0	0	1
Total other comprehensive (loss) income	(2,020)	4,492	(7,139)	8,328
Comprehensive income	36,147	319,285	96,335	387,585
Net sales
Revenues
Total revenues	241,411	270,522	734,719	784,939
Other revenues
Revenues
Total revenues	$ 3	$ 93	$ 32	$ 275

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Mar. 31, 2018
Current assets
Cash and cash equivalents	$ 24,672	$ 32,548
Accounts receivable, net of allowance of $13,444 and $12,734, respectively	140,584	140,881
Inventories	120,368	118,547
Prepaid expenses and other current assets	7,553	11,501
Total current assets	293,177	303,477
Property, plant and equipment, net	51,567	52,552
Goodwill	611,956	620,098
Intangible assets, net	2,707,825	2,780,916
Other long-term assets	3,557	3,569
Total Assets	3,668,082	3,760,612
Current liabilities
Accounts payable	48,988	61,390
Accrued interest payable	13,646	9,708
Other accrued liabilities	66,182	52,101
Total current liabilities	128,816	123,199
Long-term debt, net	1,842,288	1,992,952
Deferred income tax liabilities	443,587	442,518
Other long-term liabilities	20,271	23,333
Total Liabilities	2,434,962	2,582,002
Commitments and Contingencies — Note 16
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 53,670 shares at December 31, 2018 and 53,396 shares at March 31, 2018	536	534
Additional paid-in capital	477,872	468,783
Treasury stock, at cost - 1,871 shares at December 31, 2018 and 353 shares at March 31, 2018	(59,928)	(7,669)
Accumulated other comprehensive loss, net of tax	(26,454)	(19,315)
Retained earnings	841,094	736,277
Total Stockholders' Equity	1,233,120	1,178,610
Total Liabilities and Stockholders' Equity	$ 3,668,082	$ 3,760,612

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2018	Mar. 31, 2018
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 13,444	$ 12,734
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	53,670,000	53,396,000
Treasury stock (in shares)	1,871,000	353,000

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Activities
Net income	$ 103,474	$ 379,257
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	24,253	25,381
Gain on divestiture	(1,284)	0
Loss on disposal of property and equipment	197	1,510
Deferred income taxes	3,309	(256,850)
Amortization of debt origination costs	4,543	4,746
Excess tax benefits from share-based awards	0	470
Stock-based compensation costs	6,160	6,912
Write-off of indemnification asset	0	704
Other	247	0
Lease termination costs	0	214
Changes in operating assets and liabilities:
Accounts receivable	5,398	(14,073)
Inventories	(11,081)	1,167
Prepaid expenses and other current assets	4,073	18,935
Accounts payable	(12,787)	(11,036)
Accrued liabilities	13,260	(1,033)
Pension and deferred compensation contribution	0	(329)
Other	(1,325)	(303)
Net cash provided by operating activities	138,437	155,672
Investing Activities
Purchases of property, plant and equipment	(7,139)	(9,656)
Acquisition of Fleet escrow receipt	0	970
Proceeds from divestiture	65,912	0
Net cash provided by (used in) investing activities	58,773	(8,686)
Financing Activities
Term loan repayments	(155,000)	(125,000)
Borrowings under revolving credit agreement	45,000	20,000
Repayments under revolving credit agreement	(45,000)	(40,000)
Proceeds from exercise of stock options	2,931	1,466
Fair value of shares surrendered as payment of tax withholding	(2,281)	(1,075)
Repurchase of common stock	(49,978)	0
Net cash used in financing activities	(204,328)	(144,609)
Effects of exchange rate changes on cash and cash equivalents	(758)	1,144
(Decrease) increase in cash and cash equivalents	(7,876)	3,521
Cash and cash equivalents - beginning of period	32,548	41,855
Cash and cash equivalents - end of period	24,672	45,376
Interest paid	69,955	73,779
Income taxes paid	$ 19,070	$ 16,861

Business and Basis of Presentation

9 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business and Basis of Presentation

Nature of Business

Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products (prior to the sale of our Household Cleaning segment, as discussed in Note 3) to mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada), and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 8.

Basis of Presentation

The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31^st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2019) mean our fiscal year ending or ended on March 31^st of that year. Operating results for the three and nine months ended December 31, 2018 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2019. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2018.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates.

Reclassification

In accordance with Accounting Standards Update ("ASU") 2017-07, we have reclassified net periodic benefit costs related to our pension plans from general and administrative expense to other (income) expense. The impact of this reclassification on our financial statements was less than $1.0 million.

Recently Adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, including new FASB Accounting Standards Codification ("ASC") 606, which supersedes the revenue recognition requirements in FASB ASC 605. Along with amendments issued in 2015 and 2016, the new guidance eliminates industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue. The core principle of the new guidance is that an entity should recognize revenue for the transfer of goods and services equal to an amount it expects to be entitled to receive for those goods and services. The new standard also requires additional disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The new guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively by recognizing the cumulative effect of initially applying the guidance to all contracts existing at the date of initial application (the modified retrospective method). The ASU, as amended, is effective for annual reporting periods beginning after December 15, 2017. We adopted this guidance effective April 1, 2018 using the modified retrospective transition method and applied it to contracts that were not completed at the adoption date. See Note 2 for our revenue recognition policy.

The effects of this recently adopted accounting pronouncement to our consolidated balance sheet as of April 1, 2018 are as follows:



(In thousands)	Balance March 31, 2018		New Revenue Standard Adjustment			Balance April 1, 2018
Accounts receivable, net	$	140,881	$	5,438		$	146,319
Inventories	118,547		(1,768		)	116,779
Other accrued liabilities	52,101		1,926			54,027
Deferred income tax liabilities	442,518		401			442,919
Retained earnings	736,277		1,343			737,620

In March 2017, the FASB issued ASU 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which changes the presentation of net periodic benefit cost related to employer sponsored defined benefit plans and other postretirement benefits. Under this ASU, service cost should be included in the same income statement line item as other compensation costs arising from services rendered during the period, while other components of net periodic benefit pension cost should be presented separately outside of operating income. Additionally, only service costs may be capitalized in assets. Entities should apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. The guidance limiting the capitalization of net periodic benefit cost in assets to the service cost component should be applied prospectively. The standard is effective for annual reporting periods beginning after December 15, 2017. The adoption of this standard in the first quarter of 2019 required us to reclassify certain pension costs out of operating income and did not have a material impact on our consolidated financial statements.

In March 2018, the FASB issued ASU 2018-05, Income Taxes (Topic 740). The amendments in this update reflect the income tax accounting implications of the Tax Cuts and Jobs Act ("Tax Act"). See Note 14 for a discussion of the Tax Act, which was signed into law on December 22, 2017, and the impact it has had, and may have, on our business and financial results.

In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The amendments in this update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. See Note 14 for a discussion of the Tax Act and the impact it has had, and may have, on our business and financial results. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. We have early adopted ASU 2018-02, and the adoption did not have a material impact on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. We adopted this standard effective April 1, 2018, and the adoption did not have a material impact on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments. The amendments in this update provide clarification and guidance on eight cash flow classification issues. For public companies, the amendments in this update are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We adopted this standard effective April 1, 2018, and the adoption did not have a material impact on our consolidated financial statements.

Recently Issued Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans. The amendments in this update modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans and are effective for public companies for fiscal years ending after December 15, 2020. We do not expect the adoption of this standard to have a material impact on our financial statements.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements in Topic 820 and are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We do not expect the adoption of this standard to have a material impact on our financial statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our consolidated financial statements and whether to early adopt this ASU.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments. The amendments in this update provide financial statement users with more useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, to clarify that receivables arising from operating leases are not within the scope of the credit loss standard, but should be accounted for in accordance with the lease standard. The amendments to this update are effective for us for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of adopting this guidance on our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases. The amendments in this update include a new FASB ASC Topic 842, which supersedes Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For public companies, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. In July 2018, further guidance on this topic was issued with ASU 2018-10, Codification Improvements to Topic 842, Leases, which affects narrow aspects of the guidance in ASU 2016-02, and with ASU 2018-11, Leases (Topic 842): Targeted Improvements, which provides an additional transition method to adopt the new lease standard as well as a practical expedient. The required effective dates for the amendments issued in July 2018 are the same as those for Topic 842. In December 2018, the FASB issued ASU 2018-20, Leases (Topic 842): Narrow-Scope Improvements for Lessors, to address certain issues facing lessors when applying Topic 842. This update is effective for us upon adoption of Topic 842. We plan to adopt the standard on April 1, 2019. We are in the process of aggregating and evaluating our lease arrangements. We expect that adoption of this standard will result in a material increase in lease-related assets and liabilities recognized on our Consolidated Balance Sheet, but we are unable to quantify the impact at this time.

Revenue Recognition

9 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Revenue Recognition

Nature of Goods and Services

We recognize revenue from product sales. We primarily ship finished goods to our customers and operate in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning (prior to the sale of this segment on July 2, 2018). The segments are based on differences in the nature of products and geographical area. The North America and International OTC Healthcare segments market a variety of personal care and over-the-counter products in the following product groups: Analgesics, Cough & Cold, Women's Health, Gastrointestinal, Eye & Ear Care, Dermatologicals, and Oral Care. Prior to its sale, the Household Cleaning segment focused on the sale of cleaning products. Our products are distinct and separately identifiable on customer contracts or invoices, with each product sale representing a separate performance obligation.

We sell consumer products under a variety of brands through a broad distribution platform that includes mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels, all of which sell our products to consumers.

See Note 18 for disaggregated revenue information.

Satisfaction of Performance Obligations

Revenue is recognized when control of a promised good is transferred to a customer, in an amount that reflects the consideration that we expect to be entitled to receive in exchange for that good. This occurs either when finished goods are transferred to a common carrier for delivery to the customer or when product is picked up by the customer or the customer’s carrier. This represents a change in the timing of revenue recognition for some sales. Refer to the table above in Note 1 for disclosure of the adoption date impacts.

Once a product has transferred to the common carrier or been picked up by the customer, the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the product. It is at this point that we have a right to payment and the customer has legal title.

Variable Consideration

Provisions for certain rebates, customer promotional programs, product returns, and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales.

We record an estimate of future product returns concurrent with recording sales, which is made using the most likely amount method which incorporates (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

We participate in the promotional programs of our customers to enhance the sale of our products. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. The costs of such activities are recorded as a reduction to revenue when the related sale takes place. Estimates of the costs of these promotional programs are derived using the most likely amount method, which incorporates (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. At the completion of the promotional program, the estimated amounts are adjusted to actual results.

Practical Expedients

Due to the nature (short duration) of our contracts with customers, we apply the practical expedient related to remaining performance obligations disclosure. Remaining performance obligations relate to contracts with a duration of less than one year, in which we have the right to invoice the customer at the time the performance obligation is satisfied for the amount of revenue recognized at that time. Accordingly, we have elected the practical expedient available under ASC 606 not to disclose remaining performance obligations for our contracts. The period between when control of the promised products transfers to the customer and when the customer pays for the products is one year or less. As such, we do not adjust product consideration for the effects of a significant financing component. The amortization period of any asset resulting from incremental costs of obtaining a contract would be one year or less.

We expense incremental direct costs of obtaining a contract (broker commissions) when the related sale takes place.

We account for shipping and handling costs as fulfillment activities and therefore recognize them upon shipment of goods.

The impact of adopting ASC 606 on our Condensed Consolidated Statements of Income and Comprehensive Income is as follows:



	Three Months Ended December 31, 2018						Nine Months Ended December 31, 2018
(In thousands)	As Reported		Impact of Change		Without Adoption of ASC 606		As Reported		Impact of Change			Without Adoption of ASC 606
Total revenues	$	241,414	$	13,618	$	255,032	$	734,751	$	(8,492	)	$	726,259
Cost of sales	$	102,179	$	5,140	$	107,319	$	317,421	$	(3,256	)	$	314,165
Total operating expenses	$	61,694	$	391	$	62,085	$	196,378	$	(188	)	$	196,190
Income before income taxes	$	50,996	$	8,087	$	59,083	$	140,975	$	(5,048	)	$	135,927
Provision (benefit) for income taxes	$	12,829	$	2,038	$	14,867	$	37,501	$	(1,714	)	$	35,787
Net income	$	38,167	$	6,049	$	44,216	$	103,474	$	(3,334	)	$	100,140

Divestiture

9 Months Ended

Dec. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Divestiture

On July 2, 2018, we sold the Comet®, Spic and Span®, Chore Boy®, Chlorinol® and Cinch® brands, as well as associated inventory. These brands represented our Household Cleaning segment.

As a result of this transaction, we received proceeds of approximately $65.9 million and recorded a pre-tax gain on sale of $1.3 million. The net proceeds were used to repay debt.

The following table sets forth the components of the assets sold and the pre-tax gain recognized on the sale in July 2018:



(In thousands)	July 2, 2018
Components of assets sold:
Inventory	$	6,644
Property, plant and equipment, net	653
Goodwill	6,245
Intangible assets, net	49,315
Assets sold	62,857
Total purchase price received	65,912
	(3,055		)
Costs to sell	1,771
Pre-tax gain on divestiture	$	(1,284	)

Inventories

9 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:



(In thousands)	December 31, 2018		March 31, 2018
Components of Inventories
Packaging and raw materials	$	16,834	$	13,112
Work in process	307		157
Finished goods	103,227		105,278
Inventories	$	120,368	$	118,547

Inventories are carried and depicted above at the lower of cost or net realizable value, which includes a reduction in inventory values of $3.3 million and $4.2 million at December 31, 2018 and March 31, 2018, respectively, related to obsolete and slow-moving inventory.

Goodwill

9 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

A reconciliation of the activity affecting goodwill by operating segment is as follows:



(In thousands)		North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance - March 31, 2018
	Goodwill	$	711,104		$	32,919		$	71,405		$	815,428
	Accumulated impairment loss	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2018		580,934			32,919			6,245			620,098
	2019 Reductions:
	Goodwill	—			—			(71,405		)	(71,405		)
	Accumulated impairment loss	—			—			65,160			65,160
	Effects of foreign currency exchange rates	—			(1,897		)	—			(1,897		)
Balance - December 31, 2018
	Goodwill	711,104			31,022			—			742,126
	Accumulated impairment loss	(130,170		)	—			—			(130,170		)
Balance - December 31, 2018		$	580,934		$	31,022		$	—		$	611,956

As discussed in Note 3, on July 2, 2018, we sold our Household Cleaning segment. As a result, we decreased goodwill by $6.2 million.

Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount.

On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. At February 28, 2018, during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in fiscal 2018. We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test. We also considered our market capitalization at February 28, 2018, which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increasing competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future. As of December 31, 2018, no events have occurred that would indicate potential impairment of goodwill.

Intangible Assets, net

9 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets, net

A reconciliation of the activity affecting intangible assets, net is as follows:



(In thousands)	Indefinite- Lived Trademarks			Finite-Lived Trademarks and Customer Relationships			Totals
Gross Carrying Amounts
Balance — March 31, 2018	$	2,490,303		$	441,314		$	2,931,617
Reductions	(30,562		)	(34,889		)	(65,451		)
Effects of foreign currency exchange rates	(6,921		)	(383		)	(7,304		)
Balance — December 31, 2018	2,452,820			406,042			2,858,862

Accumulated Amortization
Balance — March 31, 2018	—			150,701			150,701
Additions	—			16,548			16,548
Reductions	—			(16,136		)	(16,136		)
Effects of foreign currency exchange rates	—			(76		)	(76		)
Balance — December 31, 2018	—			151,037			151,037

Intangible assets, net — December 31, 2018	$	2,452,820		$	255,005		$	2,707,825

As discussed in Note 3, on July 2, 2018, we sold our Household Cleaning segment. As a result, we decreased our indefinite-lived intangibles by $30.5 million and our net finite-lived trademarks by $18.8 million.

Amortization expense was $5.3 million and $16.5 million for the three and nine months ended December 31, 2018, respectively, and $5.8 million and $17.5 million for the three and nine months ended December 31, 2017, respectively. Based on our amortizable intangible assets as of December 31, 2018, amortization expense is expected to be approximately $5.4 million for the remainder of fiscal 2019, $21.5 million in fiscal 2020, $21.0 million in fiscal 2021 and $20.6 million in each of fiscal 2022, 2023 and 2024.

Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. The date of our annual impairment review was February 28, 2018, and we recorded impairment charges in our March 31, 2018 financial statements. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

We utilize the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The discount rate utilized in the analyses, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, we may be required to record impairment charges in the future.

As of December 31, 2018, no events have occurred that would indicate further potential impairment of intangible assets.

Long-Term Debt

9 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Long-Term Debt

At December 31, 2018, we had $75.0 million outstanding on the asset-based revolving credit facility entered into January 31, 2012, as amended (the "2012 ABL Revolver") and an additional borrowing capacity of $89.6 million.

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	December 31, 2018			March 31, 2018
2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024.	$	600,000		$	600,000
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	400,000			400,000
2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00%, with a floor of 1.00%, due on January 26, 2024.	783,000			938,000
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022.	75,000			75,000
Long-term debt	1,858,000			2,013,000
Less: unamortized debt costs	(15,712		)	(20,048		)
Long-term debt, net	$	1,842,288		$	1,992,952

As of December 31, 2018, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans, 2012 ABL Revolver and the indentures governing the 6.375% senior unsecured notes due 2024 (the "2016 Senior Notes") and the 5.375% senior unsecured notes due 2021 (the "2013 Senior Notes") are as follows:



(In thousands)
Year Ending March 31,	Amount
2019 (remaining three months ending March 31, 2019)	$	—
2020	—
2021	—
2022	475,000
2023	—
Thereafter	1,383,000
	$	1,858,000

Fair Value Measurements

9 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

FASB ASC 820, Fair Value Measurements, requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:

Level 1 - Quoted market prices for identical instruments in active markets;

Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and

Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant.

The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2016 Senior Notes, the 2013 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. See summary below detailing the carrying amounts and estimated fair values of these borrowings at December 31, 2018 and March 31, 2018.



	December 31, 2018				March 31, 2018
(In thousands)	Carrying Value		Fair Value		Carrying Value		Fair Value
2016 Senior Notes	$	600,000	$	582,000	$	600,000	$	610,500
2013 Senior Notes	400,000		391,000		400,000		402,000
2012 Term B-5 Loans	783,000		749,723		938,000		939,173
2012 ABL Revolver	75,000		75,000		75,000		75,000

At December 31, 2018 and March 31, 2018, we did not have any assets or liabilities measured in Level 1 or 3.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on our common stock through December 31, 2018. During the three months ended December 31, 2018 and 2017, we made no repurchases of common stock. During the nine months ended December 31, 2018 and 2017, we repurchased 68,939 shares and 20,549 shares, respectively, of common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the nine months ended December 31, 2018 and 2017 were at an average price of $33.09 and $52.33, respectively. All of the repurchased shares have been recorded as treasury stock. During the nine months ended December 31, 2018, we also repurchased 1,449,750 shares of our common stock in conjunction with our share repurchase program. The repurchases were at an average price of $34.47 per share, totaled $50.0 million, and have been recorded as treasury stock.

Accumulated Other Comprehensive Loss

9 Months Ended

Dec. 31, 2018

Stockholders' Equity Note [Abstract]

Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss consisted of the following at December 31, 2018 and March 31, 2018:



(In thousands)	December 31, 2018			March 31, 2018
Components of Accumulated Other Comprehensive Loss
Cumulative translation adjustment	$	(27,537	)	$	(20,398	)
Unrecognized net gain on pension plans	1,083			1,083
Accumulated other comprehensive loss, net of tax	$	(26,454	)	$	(19,315	)

As of December 31, 2018 and March 31, 2018, no amounts were reclassified from accumulated other comprehensive income into earnings.

Earnings Per Share

9 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Earnings Per Share

Basic earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options and restricted stock units ("RSUs"). Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and nonvested RSUs, are included in the diluted earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and RSUs has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share.

The following table sets forth the computation of basic and diluted earnings per share:



	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands, except per share data)	2018		2017		2018		2017
Numerator
Net income	$	38,167	$	314,793	$	103,474	$	379,257

Denominator
Denominator for basic earnings per share — weighted average shares outstanding	51,881		53,129		52,119		53,089
Dilutive effect of nonvested restricted stock units and options issued to employees and directors	321		414		312		442
Denominator for diluted earnings per share	52,202		53,543		52,431		53,531

Earnings per Common Share:
Basic earnings per share	$	0.74	$	5.93	$	1.99	$	7.14

Diluted earnings per share	$	0.73	$	5.88	$	1.97	$	7.08

For the three months ended December 31, 2018 and 2017, there were 0.4 million and 0.5 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the nine months ended December 31, 2018 and 2017, there were 0.5 million and 0.4 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Share-Based Compensation

9 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, RSUs and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, an increase of the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any fiscal 12-month period from 1.0 million to 2.5 million shares, and an extension of the term of the Plan by ten years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During the three and nine months ended December 31, 2018, pre-tax share-based compensation costs charged against income were $1.9 million and $6.2 million, respectively, and the related income tax benefit recognized was $0.3 million and $1.1 million, respectively. During the three and nine months ended December 31, 2017, pre-tax share-based compensation costs charged against income were $2.2 million and $6.9 million, respectively, and the related income tax recognized was an expense of $0.1 million and a benefit of $1.4 million, respectively.

At December 31, 2018, there were $7.6 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted average period of 1.0 year. The total fair value of options and RSUs vested during the nine months ended December 31, 2018 and 2017 was $12.0 million and $6.8 million, respectively. For the nine months ended December 31, 2018 and 2017, we received cash from the exercise of stock options of $2.9 million and $1.5 million, respectively. For the nine months ended December 31, 2018 and 2017, we realized $1.3 million and $1.1 million, respectively, in tax benefits from the tax deductions resulting from RSU issuances and stock option exercises. At December 31, 2018, there were 1.8 million shares available for issuance under the Plan.

On May 7, 2018, the Compensation and Talent Management Committee of our Board of Directors granted 103,406 performance stock units, 100,399 RSUs and stock options to acquire 294,484 shares of our common stock to certain executive officers and employees under the Plan. The stock options were granted at an exercise price of $29.46 per share, which was equal to the closing price for our common stock on the date of the grant.

Each of the independent members of the Board of Directors received a grant under the Plan of 3,779 RSUs on July 31, 2018.

Restricted Stock Units

RSUs granted to employees under the Plan generally vest in three years, primarily upon the attainment of certain time vesting thresholds, and, in the case of performance share units, may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The RSUs provide for accelerated vesting if there is a change of control, as defined in the Plan. The RSUs granted to employees generally vest either ratably over three years or in their entirety on the three-year anniversary of the date of the grant. Upon vesting, the units will be settled in shares of our common stock. Termination of employment prior to vesting will result in forfeiture of the RSUs, unless otherwise accelerated by the Compensation and Talent Management Committee or, in the case of RSUs granted in May 2017 and 2018, subject to pro-rata vesting in the event of death, disability or retirement. The RSUs granted to directors vest immediately upon grant, and will be settled by delivery to the director of one share of our common stock for each vested RSU promptly following the earliest of the (i) director's death, (ii) director's disability or (iii) six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability.

The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant.

A summary of the RSUs granted under the Plan is presented below:



RSUs	Shares (in thousands)		Weighted Average Grant-Date Fair Value
Nine Months Ended December 31, 2017
Vested and nonvested at March 31, 2017	350.1		$	39.29
Granted	105.8		55.61
Vested and issued	(53.3	)	34.30
Forfeited	(8.8	)	48.49
Vested and nonvested at December 31, 2017	393.8		44.14
Vested at December 31, 2017	90.5		29.88

Nine Months Ended December 31, 2018
Vested and nonvested at March 31, 2018	393.5		$	44.13
Granted	226.4		30.09
Vested and issued	(175.8	)	43.05
Forfeited	(31.1	)	48.32
Vested and nonvested at December 31, 2018	413.0		36.58
Vested at December 31, 2018	113.2		31.05

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of our common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Except in the case of death, disability or retirement, termination of employment prior to vesting will result in forfeiture of the nonvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms in the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management's estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options.

The weighted average grant-date fair values of the options granted during the nine months ended December 31, 2018 and 2017 were $10.22 and $21.20, respectively.



	Nine Months Ended December 31,
	2018			2017
Expected volatility	29.6		%	35.2		%
Expected dividends	$	—		$	—
Expected term in years	6.0			6.0
Risk-free rate	2.9		%	2.2		%

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Nine Months Ended December 31, 2017
Outstanding at March 31, 2017	772.3		$	37.70
Granted	182.8		56.11
Exercised	(51.0	)	28.76
Forfeited or expired	(22.1	)	48.15
Outstanding at December 31, 2017	882.0		41.77		7.2	$	7,019
Exercisable at December 31, 2017	502.9		32.50		6.1	$	6,884

Nine Months Ended December 31, 2018
Outstanding at March 31, 2018	873.2		$	41.79
Granted	294.5		29.46
Exercised	(97.7	)	30.02
Forfeited or expired	(125.4	)	47.16
Outstanding at December 31, 2018	944.6		38.45		7.2	$	2,477
Exercisable at December 31, 2018	499.4		37.87		5.8	$	2,076

The aggregate intrinsic value of options exercised during the nine months ended December 31, 2018 was $0.8 million.

Income Taxes	9 Months Ended
Income Taxes	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Act. The Tax Act represents significant U.S. federal tax reform legislation that includes a permanent reduction to the U.S. federal corporate income tax rate. The permanent reduction to the federal corporate income tax rate resulted in a one-time gain of $267.0 million related to the value of our deferred tax liabilities and a gain of $3.2 million related to the lower blended tax rate on our earnings, in the year ended March 31, 2018, resulting in a net gain of $270.2 million. Additionally, the Tax Act subjects certain of our cumulative foreign earnings and profits to U.S. income taxes through a deemed repatriation, which resulted in a charge of $1.9 million in the year ended March 31, 2018. Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective rates used in the calculation of income taxes were 25.2% and (446.1)% for the three months ended December 31, 2018 and 2017, respectively. The effective rates used in the calculation of income taxes were 26.6% and (137.6)% for the nine months ended December 31, 2018 and 2017, respectively. The increases in the effective tax rates for the three and nine months ended December 31, 2018 versus the respective prior year periods were primarily related to the Tax Act being enacted in the prior year periods, which included a one-time gain as discussed above. The balance in our uncertain tax liability was $9.8 million at December 31, 2018 and $10.8 million at March 31, 2018. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in any of the periods presented.

Employee Retirement Plans

9 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Employee Retirement Plans

The primary components of Net Periodic Benefits consist of the following:



	Three Months Ended December 31,						Nine Months Ended December 31,
(In thousands)	2018			2017			2018			2017
Interest cost	$	599		$	631		$	1,819		$	1,894
Expected return on assets	(767		)	(725		)	(2,303		)	(2,176		)
Net periodic benefit income	$	(168	)	$	(94	)	$	(484	)	$	(282	)

During the nine months ended December 31, 2018, we contributed $0.3 million to our non-qualified defined benefit plan and $1.0 million to the qualified defined benefit plan. During the remainder of fiscal 2019, we expect to contribute an additional $0.1 million to our non-qualified plan and make no contributions to the qualified plan.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations.

Concentrations of Risk	9 Months Ended
Concentrations of Risk	Dec. 31, 2018
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products (prior to the sale of our Household Cleaning segment, as discussed in Note 3). We sell our products to mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels. During the three and nine months ended December 31, 2018, approximately 41.7% and 42.8%, respectively, of our gross revenues were derived from our five top selling brands. During the three and nine months ended December 31, 2017, approximately 39.9% and 41.2%, respectively, of our gross revenues were derived from our five top selling brands. One customer, Walmart accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 22.3% and 23.5%, respectively, of our gross revenues for the three and nine months ended December 31, 2018. For the three and nine months ended December 31, 2017, Walmart accounted for approximately 21.4% and 24.0%, respectively, of our gross revenues. The gross revenues for Walmart are included in our North American OTC Healthcare segment and Household Cleaning segment (prior to the sale of our Household Cleaning segment on July 2, 2018). Our product distribution in the United States is managed by a third party through one primary distribution center near St. Louis, Missouri, and we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia. A serious disruption, caused by performance or contractual issues with the third party distribution manager or by earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. Any disruption as a result of third party performance at our distribution center could result in increased costs, expense, shipping times, customer fees and penalties. In addition, any serious disruption to our Lynchburg manufacturing facility could materially impair our ability to manufacture many of our products, which would also limit our ability to provide products to customers in a timely manner or at a reasonable cost. We could also incur significantly higher costs and experience longer lead times if we need to replace our primary distribution center, the third party distribution manager or the manufacturing facility. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations. At December 31, 2018, we had relationships with 112 third-party manufacturers. Of those, we had long-term contracts with 33 manufacturers that produced items that accounted for approximately 60.4% of gross sales for the nine months ended December 31, 2018. At December 31, 2017, we had relationships with 114 third-party manufacturers. Of those, we had long-term contracts with 46 manufacturers that produced items that accounted for approximately 74.2% of gross sales for the nine months ended December 31, 2017. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

9 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Business Segments

Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We sold our Household Cleaning segment on July 2, 2018; see Note 3 for further information. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses.

The tables below summarize information about our reportable segments.



	Three Months Ended December 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	216,776	$	24,638	$	—	$	241,414
Cost of sales	91,594		10,585		—		102,179
Gross profit	125,182		14,053		—		139,235
Advertising and promotion	30,316		4,188		—		34,504
Contribution margin	$	94,866	$	9,865	$	—	104,731
Other operating expenses							27,190
Operating income							77,541
Other expense							26,545
Income before income taxes							50,996
Provision for income taxes							12,829
Net income							$	38,167

* Intersegment revenues of $1.3 million were eliminated from the North American OTC Healthcare segment.



	Nine Months Ended December 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	647,501	$	67,439	$	19,811	$	734,751
Cost of sales	272,754		28,079		16,588		317,421
Gross profit	374,747		39,360		3,223		417,330
Advertising and promotion	96,899		11,328		430		108,657
Contribution margin	$	277,848	$	28,032	$	2,793	308,673
Other operating expenses							87,721
Operating income							220,952
Other expense							79,977
Income before income taxes							140,975
Provision for income taxes							37,501
Net income							$	103,474

* Intersegment revenues of $5.6 million were eliminated from the North American OTC Healthcare segment.



	Three Months Ended December 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	225,695	$	25,717	$	19,203	$	270,615
Cost of sales	95,164		10,511		17,266		122,941
Gross profit	130,531		15,206		1,937		147,674
Advertising and promotion	30,794		4,544		497		35,835
Contribution margin	$	99,737	$	10,662	$	1,440	111,839
Other operating expenses							27,949
Operating income							83,890
Other expense							26,251
Income before income taxes							57,639
Benefit for income taxes							(257,154		)
Net income							$	314,793

* Intersegment revenues of $1.9 million were eliminated from the North American OTC Healthcare segment.



	Nine Months Ended December 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	656,812	$	67,572	$	60,830	$	785,214
Cost of sales	268,849		29,757		51,360		349,966
Gross profit	387,963		37,815		9,470		435,248
Advertising and promotion	98,666		11,827		1,474		111,967
Contribution margin	$	289,297	$	25,988	$	7,996	323,281
Other operating expenses							84,711
Operating income							238,570
Other expense							78,922
Income before income taxes							159,648
Benefit for income taxes							(219,609		)
Net income							$	379,257

* Intersegment revenues of $5.6 million were eliminated from the North American OTC Healthcare segment.

The tables below summarize information about our segment revenues from similar product groups.



	Three Months Ended December 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	29,325	$	136	$	—	$	29,461
Cough & Cold	27,137		4,584		—		31,721
Women's Health	60,946		3,306		—		64,252
Gastrointestinal	30,737		10,321		—		41,058
Eye & Ear Care	23,352		3,164		—		26,516
Dermatologicals	21,508		470		—		21,978
Oral Care	22,177		2,656		—		24,833
Other OTC	1,594		1		—		1,595
Household Cleaning	—		—		—		—
Total segment revenues	$	216,776	$	24,638	$	—	$	241,414



	Nine Months Ended December 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	86,221	$	418	$	—	$	86,639
Cough & Cold	63,843		15,489		—		79,332
Women's Health	186,037		8,833		—		194,870
Gastrointestinal	94,065		24,261		—		118,326
Eye & Ear Care	73,669		8,778		—		82,447
Dermatologicals	71,968		1,607		—		73,575
Oral Care	67,516		8,050		—		75,566
Other OTC	4,182		3		—		4,185
Household Cleaning	—		—		19,811		19,811
Total segment revenues	$	647,501	$	67,439	$	19,811	$	734,751



	Three Months Ended December 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	31,293	$	160	$	—	$	31,453
Cough & Cold	28,761		4,331		—		33,092
Women's Health	63,107		2,940		—		66,047
Gastrointestinal	29,392		11,251		—		40,643
Eye & Ear Care	21,631		3,205		—		24,836
Dermatologicals	22,736		562		—		23,298
Oral Care	27,144		3,267		—		30,411
Other OTC	1,631		1		—		1,632
Household Cleaning	—		—		19,203		19,203
Total segment revenues	$	225,695	$	25,717	$	19,203	$	270,615



	Nine Months Ended December 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	89,931	$	709	$	—	$	90,640
Cough & Cold	67,738		13,603		—		81,341
Women's Health	187,688		8,440		—		196,128
Gastrointestinal	88,145		25,123		—		113,268
Eye & Ear Care	69,437		8,850		—		78,287
Dermatologicals	72,688		1,587		—		74,275
Oral Care	77,026		9,256		—		86,282
Other OTC	4,159		4		—		4,163
Household Cleaning	—		—		60,830		60,830
Total segment revenues	$	656,812	$	67,572	$	60,830	$	785,214

Our total segment revenues by geographic area are as follows:



	Three Months Ended December 31,				Nine Months Ended December 31,
	2018		2017		2018		2017
United States	$	204,943	$	232,583	$	632,183	$	682,928
Rest of world	36,471		38,032		102,568		102,286
Total	$	241,414	$	270,615	$	734,751	$	785,214

Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



December 31, 2018	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
(In thousands)
Goodwill	$	580,934	$	31,022	$	—	$	611,956

Intangible assets
Indefinite-lived	2,375,735		77,085		—		2,452,820
Finite-lived, net	249,637		5,368		—		255,005
Intangible assets, net	2,625,372		82,453		—		2,707,825
Total	$	3,206,306	$	113,475	$	—	$	3,319,781



March 31, 2018	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
(In thousands)
Goodwill	$	580,934	$	32,919	$	6,245	$	620,098

Intangible assets
Indefinite-lived	2,375,736		84,006		30,561		2,490,303
Finite-lived, net	265,356		6,068		19,189		290,613
Intangible assets, net	2,641,092		90,074		49,750		2,780,916
Total	$	3,222,026	$	122,993	$	55,995	$	3,401,014

Business and Basis of Presentation (Policies)

9 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Use of Estimates

Reclassification

Recently Adopted and Issued Accounting Standards

Recently Adopted Accounting Pronouncements

The effects of this recently adopted accounting pronouncement to our consolidated balance sheet as of April 1, 2018 are as follows:



(In thousands)	Balance March 31, 2018		New Revenue Standard Adjustment			Balance April 1, 2018
Accounts receivable, net	$	140,881	$	5,438		$	146,319
Inventories	118,547		(1,768		)	116,779
Other accrued liabilities	52,101		1,926			54,027
Deferred income tax liabilities	442,518		401			442,919
Retained earnings	736,277		1,343			737,620

Recently Issued Accounting Pronouncements

Revenue Recognition

Nature of Goods and Services

See Note 18 for disaggregated revenue information.

Satisfaction of Performance Obligations

Variable Consideration

Provisions for certain rebates, customer promotional programs, product returns, and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales.

Practical Expedients

We expense incremental direct costs of obtaining a contract (broker commissions) when the related sale takes place.

We account for shipping and handling costs as fulfillment activities and therefore recognize them upon shipment of goods.

Business and Basis of Presentation (Tables)

9 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Effects of Recently Adopted Accounting Pronouncement

The effects of this recently adopted accounting pronouncement to our consolidated balance sheet as of April 1, 2018 are as follows:



(In thousands)	Balance March 31, 2018		New Revenue Standard Adjustment			Balance April 1, 2018
Accounts receivable, net	$	140,881	$	5,438		$	146,319
Inventories	118,547		(1,768		)	116,779
Other accrued liabilities	52,101		1,926			54,027
Deferred income tax liabilities	442,518		401			442,919
Retained earnings	736,277		1,343			737,620

The impact of adopting ASC 606 on our Condensed Consolidated Statements of Income and Comprehensive Income is as follows:



	Three Months Ended December 31, 2018						Nine Months Ended December 31, 2018
(In thousands)	As Reported		Impact of Change		Without Adoption of ASC 606		As Reported		Impact of Change			Without Adoption of ASC 606
Total revenues	$	241,414	$	13,618	$	255,032	$	734,751	$	(8,492	)	$	726,259
Cost of sales	$	102,179	$	5,140	$	107,319	$	317,421	$	(3,256	)	$	314,165
Total operating expenses	$	61,694	$	391	$	62,085	$	196,378	$	(188	)	$	196,190
Income before income taxes	$	50,996	$	8,087	$	59,083	$	140,975	$	(5,048	)	$	135,927
Provision (benefit) for income taxes	$	12,829	$	2,038	$	14,867	$	37,501	$	(1,714	)	$	35,787
Net income	$	38,167	$	6,049	$	44,216	$	103,474	$	(3,334	)	$	100,140

Revenue Recognition (Tables)

9 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Reconciliation of Revenue

The effects of this recently adopted accounting pronouncement to our consolidated balance sheet as of April 1, 2018 are as follows:



(In thousands)	Balance March 31, 2018		New Revenue Standard Adjustment			Balance April 1, 2018
Accounts receivable, net	$	140,881	$	5,438		$	146,319
Inventories	118,547		(1,768		)	116,779
Other accrued liabilities	52,101		1,926			54,027
Deferred income tax liabilities	442,518		401			442,919
Retained earnings	736,277		1,343			737,620

The impact of adopting ASC 606 on our Condensed Consolidated Statements of Income and Comprehensive Income is as follows:



	Three Months Ended December 31, 2018						Nine Months Ended December 31, 2018
(In thousands)	As Reported		Impact of Change		Without Adoption of ASC 606		As Reported		Impact of Change			Without Adoption of ASC 606
Total revenues	$	241,414	$	13,618	$	255,032	$	734,751	$	(8,492	)	$	726,259
Cost of sales	$	102,179	$	5,140	$	107,319	$	317,421	$	(3,256	)	$	314,165
Total operating expenses	$	61,694	$	391	$	62,085	$	196,378	$	(188	)	$	196,190
Income before income taxes	$	50,996	$	8,087	$	59,083	$	140,975	$	(5,048	)	$	135,927
Provision (benefit) for income taxes	$	12,829	$	2,038	$	14,867	$	37,501	$	(1,714	)	$	35,787
Net income	$	38,167	$	6,049	$	44,216	$	103,474	$	(3,334	)	$	100,140

Divestiture (Tables)

9 Months Ended

Dec. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Divestiture

The following table sets forth the components of the assets sold and the pre-tax gain recognized on the sale in July 2018:



(In thousands)	July 2, 2018
Components of assets sold:
Inventory	$	6,644
Property, plant and equipment, net	653
Goodwill	6,245
Intangible assets, net	49,315
Assets sold	62,857
Total purchase price received	65,912
	(3,055		)
Costs to sell	1,771
Pre-tax gain on divestiture	$	(1,284	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Inventories (Tables)

9 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:



(In thousands)	December 31, 2018		March 31, 2018
Components of Inventories
Packaging and raw materials	$	16,834	$	13,112
Work in process	307		157
Finished goods	103,227		105,278
Inventories	$	120,368	$	118,547

Goodwill (Tables)

9 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Reconciliation of the Activity Affecting Goodwill

A reconciliation of the activity affecting goodwill by operating segment is as follows:



(In thousands)		North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance - March 31, 2018
	Goodwill	$	711,104		$	32,919		$	71,405		$	815,428
	Accumulated impairment loss	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2018		580,934			32,919			6,245			620,098
	2019 Reductions:
	Goodwill	—			—			(71,405		)	(71,405		)
	Accumulated impairment loss	—			—			65,160			65,160
	Effects of foreign currency exchange rates	—			(1,897		)	—			(1,897		)
Balance - December 31, 2018
	Goodwill	711,104			31,022			—			742,126
	Accumulated impairment loss	(130,170		)	—			—			(130,170		)
Balance - December 31, 2018		$	580,934		$	31,022		$	—		$	611,956

Intangible Assets, net (Tables)

9 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Reconciliation of the Activity Affecting Finite Lived Intangible Assets

A reconciliation of the activity affecting intangible assets, net is as follows:



(In thousands)	Indefinite- Lived Trademarks			Finite-Lived Trademarks and Customer Relationships			Totals
Gross Carrying Amounts
Balance — March 31, 2018	$	2,490,303		$	441,314		$	2,931,617
Reductions	(30,562		)	(34,889		)	(65,451		)
Effects of foreign currency exchange rates	(6,921		)	(383		)	(7,304		)
Balance — December 31, 2018	2,452,820			406,042			2,858,862

Accumulated Amortization
Balance — March 31, 2018	—			150,701			150,701
Additions	—			16,548			16,548
Reductions	—			(16,136		)	(16,136		)
Effects of foreign currency exchange rates	—			(76		)	(76		)
Balance — December 31, 2018	—			151,037			151,037

Intangible assets, net — December 31, 2018	$	2,452,820		$	255,005		$	2,707,825

Reconciliation of the Activity Affecting Indefinite Lived Intangible Assets

A reconciliation of the activity affecting intangible assets, net is as follows:



(In thousands)	Indefinite- Lived Trademarks			Finite-Lived Trademarks and Customer Relationships			Totals
Gross Carrying Amounts
Balance — March 31, 2018	$	2,490,303		$	441,314		$	2,931,617
Reductions	(30,562		)	(34,889		)	(65,451		)
Effects of foreign currency exchange rates	(6,921		)	(383		)	(7,304		)
Balance — December 31, 2018	2,452,820			406,042			2,858,862

Accumulated Amortization
Balance — March 31, 2018	—			150,701			150,701
Additions	—			16,548			16,548
Reductions	—			(16,136		)	(16,136		)
Effects of foreign currency exchange rates	—			(76		)	(76		)
Balance — December 31, 2018	—			151,037			151,037

Intangible assets, net — December 31, 2018	$	2,452,820		$	255,005		$	2,707,825

Long-Term Debt (Tables)

9 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	December 31, 2018			March 31, 2018
2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024.	$	600,000		$	600,000
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	400,000			400,000
2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00%, with a floor of 1.00%, due on January 26, 2024.	783,000			938,000
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022.	75,000			75,000
Long-term debt	1,858,000			2,013,000
Less: unamortized debt costs	(15,712		)	(20,048		)
Long-term debt, net	$	1,842,288		$	1,992,952

Aggregate Future Principal Payments



(In thousands)
Year Ending March 31,	Amount
2019 (remaining three months ending March 31, 2019)	$	—
2020	—
2021	—
2022	475,000
2023	—
Thereafter	1,383,000
	$	1,858,000

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Fair Value Measurements (Tables)

9 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Summary of Carry Amounts and Fair Value Measurements

As such, the 2016 Senior Notes, the 2013 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. See summary below detailing the carrying amounts and estimated fair values of these borrowings at December 31, 2018 and March 31, 2018.



	December 31, 2018				March 31, 2018
(In thousands)	Carrying Value		Fair Value		Carrying Value		Fair Value
2016 Senior Notes	$	600,000	$	582,000	$	600,000	$	610,500
2013 Senior Notes	400,000		391,000		400,000		402,000
2012 Term B-5 Loans	783,000		749,723		938,000		939,173
2012 ABL Revolver	75,000		75,000		75,000		75,000

Earnings Per Share (Tables)

9 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:



	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands, except per share data)	2018		2017		2018		2017
Numerator
Net income	$	38,167	$	314,793	$	103,474	$	379,257

Denominator
Denominator for basic earnings per share — weighted average shares outstanding	51,881		53,129		52,119		53,089
Dilutive effect of nonvested restricted stock units and options issued to employees and directors	321		414		312		442
Denominator for diluted earnings per share	52,202		53,543		52,431		53,531

Earnings per Common Share:
Basic earnings per share	$	0.74	$	5.93	$	1.99	$	7.14

Diluted earnings per share	$	0.73	$	5.88	$	1.97	$	7.08

Share-Based Compensation (Tables)

9 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Restricted Shares

A summary of the RSUs granted under the Plan is presented below:



RSUs	Shares (in thousands)		Weighted Average Grant-Date Fair Value
Nine Months Ended December 31, 2017
Vested and nonvested at March 31, 2017	350.1		$	39.29
Granted	105.8		55.61
Vested and issued	(53.3	)	34.30
Forfeited	(8.8	)	48.49
Vested and nonvested at December 31, 2017	393.8		44.14
Vested at December 31, 2017	90.5		29.88

Nine Months Ended December 31, 2018
Vested and nonvested at March 31, 2018	393.5		$	44.13
Granted	226.4		30.09
Vested and issued	(175.8	)	43.05
Forfeited	(31.1	)	48.32
Vested and nonvested at December 31, 2018	413.0		36.58
Vested at December 31, 2018	113.2		31.05

Fair Value of Options Granted

The weighted average grant-date fair values of the options granted during the nine months ended December 31, 2018 and 2017 were $10.22 and $21.20, respectively.



	Nine Months Ended December 31,
	2018			2017
Expected volatility	29.6		%	35.2		%
Expected dividends	$	—		$	—
Expected term in years	6.0			6.0
Risk-free rate	2.9		%	2.2		%

Stock Option Activity

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Nine Months Ended December 31, 2017
Outstanding at March 31, 2017	772.3		$	37.70
Granted	182.8		56.11
Exercised	(51.0	)	28.76
Forfeited or expired	(22.1	)	48.15
Outstanding at December 31, 2017	882.0		41.77		7.2	$	7,019
Exercisable at December 31, 2017	502.9		32.50		6.1	$	6,884

Nine Months Ended December 31, 2018
Outstanding at March 31, 2018	873.2		$	41.79
Granted	294.5		29.46
Exercised	(97.7	)	30.02
Forfeited or expired	(125.4	)	47.16
Outstanding at December 31, 2018	944.6		38.45		7.2	$	2,477
Exercisable at December 31, 2018	499.4		37.87		5.8	$	2,076

Employee Retirement Plans (Tables)

9 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Primary Components of Net Periodic Benefits

The primary components of Net Periodic Benefits consist of the following:



	Three Months Ended December 31,						Nine Months Ended December 31,
(In thousands)	2018			2017			2018			2017
Interest cost	$	599		$	631		$	1,819		$	1,894
Expected return on assets	(767		)	(725		)	(2,303		)	(2,176		)
Net periodic benefit income	$	(168	)	$	(94	)	$	(484	)	$	(282	)

Business Segments (Tables)

9 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Information about our Operating and Reportable Segments

The tables below summarize information about our reportable segments.



	Three Months Ended December 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	216,776	$	24,638	$	—	$	241,414
Cost of sales	91,594		10,585		—		102,179
Gross profit	125,182		14,053		—		139,235
Advertising and promotion	30,316		4,188		—		34,504
Contribution margin	$	94,866	$	9,865	$	—	104,731
Other operating expenses							27,190
Operating income							77,541
Other expense							26,545
Income before income taxes							50,996
Provision for income taxes							12,829
Net income							$	38,167

* Intersegment revenues of $1.3 million were eliminated from the North American OTC Healthcare segment.



	Nine Months Ended December 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	647,501	$	67,439	$	19,811	$	734,751
Cost of sales	272,754		28,079		16,588		317,421
Gross profit	374,747		39,360		3,223		417,330
Advertising and promotion	96,899		11,328		430		108,657
Contribution margin	$	277,848	$	28,032	$	2,793	308,673
Other operating expenses							87,721
Operating income							220,952
Other expense							79,977
Income before income taxes							140,975
Provision for income taxes							37,501
Net income							$	103,474

* Intersegment revenues of $5.6 million were eliminated from the North American OTC Healthcare segment.



	Three Months Ended December 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	225,695	$	25,717	$	19,203	$	270,615
Cost of sales	95,164		10,511		17,266		122,941
Gross profit	130,531		15,206		1,937		147,674
Advertising and promotion	30,794		4,544		497		35,835
Contribution margin	$	99,737	$	10,662	$	1,440	111,839
Other operating expenses							27,949
Operating income							83,890
Other expense							26,251
Income before income taxes							57,639
Benefit for income taxes							(257,154		)
Net income							$	314,793

* Intersegment revenues of $1.9 million were eliminated from the North American OTC Healthcare segment.



	Nine Months Ended December 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	656,812	$	67,572	$	60,830	$	785,214
Cost of sales	268,849		29,757		51,360		349,966
Gross profit	387,963		37,815		9,470		435,248
Advertising and promotion	98,666		11,827		1,474		111,967
Contribution margin	$	289,297	$	25,988	$	7,996	323,281
Other operating expenses							84,711
Operating income							238,570
Other expense							78,922
Income before income taxes							159,648
Benefit for income taxes							(219,609		)
Net income							$	379,257

* Intersegment revenues of $5.6 million were eliminated from the North American OTC Healthcare segment.

Information about our Revenues from Similar Product Groups

The tables below summarize information about our segment revenues from similar product groups.



	Three Months Ended December 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	29,325	$	136	$	—	$	29,461
Cough & Cold	27,137		4,584		—		31,721
Women's Health	60,946		3,306		—		64,252
Gastrointestinal	30,737		10,321		—		41,058
Eye & Ear Care	23,352		3,164		—		26,516
Dermatologicals	21,508		470		—		21,978
Oral Care	22,177		2,656		—		24,833
Other OTC	1,594		1		—		1,595
Household Cleaning	—		—		—		—
Total segment revenues	$	216,776	$	24,638	$	—	$	241,414



	Nine Months Ended December 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	86,221	$	418	$	—	$	86,639
Cough & Cold	63,843		15,489		—		79,332
Women's Health	186,037		8,833		—		194,870
Gastrointestinal	94,065		24,261		—		118,326
Eye & Ear Care	73,669		8,778		—		82,447
Dermatologicals	71,968		1,607		—		73,575
Oral Care	67,516		8,050		—		75,566
Other OTC	4,182		3		—		4,185
Household Cleaning	—		—		19,811		19,811
Total segment revenues	$	647,501	$	67,439	$	19,811	$	734,751



	Three Months Ended December 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	31,293	$	160	$	—	$	31,453
Cough & Cold	28,761		4,331		—		33,092
Women's Health	63,107		2,940		—		66,047
Gastrointestinal	29,392		11,251		—		40,643
Eye & Ear Care	21,631		3,205		—		24,836
Dermatologicals	22,736		562		—		23,298
Oral Care	27,144		3,267		—		30,411
Other OTC	1,631		1		—		1,632
Household Cleaning	—		—		19,203		19,203
Total segment revenues	$	225,695	$	25,717	$	19,203	$	270,615



	Nine Months Ended December 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	89,931	$	709	$	—	$	90,640
Cough & Cold	67,738		13,603		—		81,341
Women's Health	187,688		8,440		—		196,128
Gastrointestinal	88,145		25,123		—		113,268
Eye & Ear Care	69,437		8,850		—		78,287
Dermatologicals	72,688		1,587		—		74,275
Oral Care	77,026		9,256		—		86,282
Other OTC	4,159		4		—		4,163
Household Cleaning	—		—		60,830		60,830
Total segment revenues	$	656,812	$	67,572	$	60,830	$	785,214

Information about our Segment Revenues by Geographic Area

Our total segment revenues by geographic area are as follows:



	Three Months Ended December 31,				Nine Months Ended December 31,
	2018		2017		2018		2017
United States	$	204,943	$	232,583	$	632,183	$	682,928
Rest of world	36,471		38,032		102,568		102,286
Total	$	241,414	$	270,615	$	734,751	$	785,214

Information about our Consolidated Goodwill and Intangible Assets Allocated to Reportable Segments

Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



December 31, 2018	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
(In thousands)
Goodwill	$	580,934	$	31,022	$	—	$	611,956

Intangible assets
Indefinite-lived	2,375,735		77,085		—		2,452,820
Finite-lived, net	249,637		5,368		—		255,005
Intangible assets, net	2,625,372		82,453		—		2,707,825
Total	$	3,206,306	$	113,475	$	—	$	3,319,781



March 31, 2018	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
(In thousands)
Goodwill	$	580,934	$	32,919	$	6,245	$	620,098

Intangible assets
Indefinite-lived	2,375,736		84,006		30,561		2,490,303
Finite-lived, net	265,356		6,068		19,189		290,613
Intangible assets, net	2,641,092		90,074		49,750		2,780,916
Total	$	3,222,026	$	122,993	$	55,995	$	3,401,014

Business and Basis of Presentation (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
General and administrative (less than $1.0 million)	$ (20,485)	$ (20,820)	$ (68,460)	$ (63,229)
Other expense (income), net	$ 218	$ 387	640	$ (119)
Accounting Standards Update 2017-07
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
General and administrative (less than $1.0 million)			1,000
Other expense (income), net			$ 1,000

Business and Basis of Presentation (Effects of Recently Adopted Accounting Pronouncement) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Apr. 01, 2018	Mar. 31, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	$ 140,584	$ 146,319	$ 140,881
Inventories	120,368	116,779	118,547
Other accrued liabilities	66,182	54,027	52,101
Deferred income tax liabilities	443,587	442,919	442,518
Retained earnings	$ 841,094	737,620	736,277
Calculated under Revenue Guidance in Effect before Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net			140,881
Inventories			118,547
Other accrued liabilities			52,101
Deferred income tax liabilities			442,518
Retained earnings			$ 736,277
Difference between Revenue Guidance in Effect before and after Topic 606 \| New Revenue Standard Adjustment
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net		5,438
Inventories		(1,768)
Other accrued liabilities		1,926
Deferred income tax liabilities		401
Retained earnings		$ 1,343

Revenue Recognition (Narrative) (Details)	9 Months Ended
Revenue Recognition (Narrative) (Details)	Dec. 31, 2018 segment
Revenue from Contract with Customer [Abstract]
Number of operating segments	3
Contract duration	less than one year
Amortization period	1 year

Revenue Recognition (Revenue Reconciliation) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total revenues	$ 241,414	$ 270,615	$ 734,751	$ 785,214
Cost of sales	102,179	122,941	317,421	349,966
Total operating expenses	61,694	63,784	196,378	196,678
Income before income taxes	50,996	57,639	140,975	159,648
Provision (benefit) for income taxes	12,829	(257,154)	37,501	(219,609)
Net income	38,167	$ 314,793	103,474	$ 379,257
Impact of Change \| New Revenue Standard Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total revenues	13,618		(8,492)
Cost of sales	5,140		(3,256)
Total operating expenses	391		(188)
Income before income taxes	8,087		(5,048)
Provision (benefit) for income taxes	2,038		(1,714)
Net income	6,049		(3,334)
Without Adoption of ASC 606
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total revenues	255,032		726,259
Cost of sales	107,319		314,165
Total operating expenses	62,085		196,190
Income before income taxes	59,083		135,927
Provision (benefit) for income taxes	14,867		35,787
Net income	$ 44,216		$ 100,140

Divestiture (Details) - Household Cleaning - Disposed of by sale $ in Thousands	Jul. 02, 2018 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventory	$ 6,644
Property, plant and equipment, net	653
Goodwill	6,245
Intangible assets, net	49,315
Assets sold	62,857
Total purchase price received	65,912
Pre-tax gross gain on divestitures	(3,055)
Costs to sell	1,771
Pre-tax gain on divestiture	$ (1,284)

Inventories (Components of Inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Apr. 01, 2018	Mar. 31, 2018
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 16,834		$ 13,112
Work in process	307		157
Finished goods	103,227		105,278
Inventories	120,368	$ 116,779	118,547
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 3,300		$ 4,200

Goodwill (Schedule of Segment Goodwill) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2018	Mar. 31, 2018
Goodwill [Line Items]
Goodwill	$ 742,126,000	$ 815,428,000
Accumulated impairment loss	(130,170,000)	(195,330,000)
Goodwill [Roll Forward]
Balance — March 31, 2018	620,098,000
Goodwill	(71,405,000)
Accumulated impairment loss	65,160,000	0
Effects of foreign currency exchange rates	(1,897,000)
Balance - December 31, 2018	611,956,000	620,098,000
North American OTC Healthcare
Goodwill [Line Items]
Goodwill	711,104,000	711,104,000
Accumulated impairment loss	(130,170,000)	(130,170,000)
Goodwill [Roll Forward]
Balance — March 31, 2018	580,934,000
Goodwill	0
Accumulated impairment loss	0
Effects of foreign currency exchange rates	0
Balance - December 31, 2018	580,934,000	580,934,000
International OTC Healthcare
Goodwill [Line Items]
Goodwill	31,022,000	32,919,000
Accumulated impairment loss	0	0
Goodwill [Roll Forward]
Balance — March 31, 2018	32,919,000
Goodwill	0
Accumulated impairment loss	0
Effects of foreign currency exchange rates	(1,897,000)
Balance - December 31, 2018	31,022,000	32,919,000
Household Cleaning
Goodwill [Line Items]
Goodwill	0	71,405,000
Accumulated impairment loss	0	(65,160,000)
Goodwill [Roll Forward]
Balance — March 31, 2018	6,245,000
Goodwill	(71,405,000)
Accumulated impairment loss	65,160,000
Effects of foreign currency exchange rates	0
Balance - December 31, 2018	$ 0	$ 6,245,000

Goodwill (Narrative) (Details) - USD ($)	9 Months Ended	12 Months Ended
Goodwill (Narrative) (Details) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Goodwill [Line Items]
Goodwill impairment	$ 65,160,000	$ 0
Household Cleaning
Goodwill [Line Items]
Decrease in goodwill related to sell of segment	6,200,000
Goodwill impairment	$ 65,160,000

Intangible Assets, net (Schedule of Reconciliation of Activity Affecting Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2018
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-Lived Trademarks, beginning balance			$ 2,490,303
Indefinite-Lived Trademarks, ending balance	$ 2,452,820		2,452,820
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-Lived Trademarks and Customer Relationships, accumulated amortization, beginning balance			150,701
Accumulated amortization, additions	5,300	$ 5,800	16,548	$ 17,500
Accumulated amortization, reductions			(16,136)
Accumulated amortization, effects of foreign exchange rates			(76)
Finite-Lived Trademarks and Customer Relationships, accumulated amortization, ending balance	151,037		151,037
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance			2,931,617
Totals, gross, reductions			(65,451)
Totals, effects of foreign currency exchange rate			(7,304)
Totals, gross, ending balance	2,858,862		2,858,862
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived, net	255,005		255,005		$ 290,613
Intangible Assets, Net [Abstract]
Intangible assets, net	2,707,825		2,707,825		$ 2,780,916
Finite-Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-Lived Trademarks and Customer Relationships, beginning balance			441,314
Finite-Lived Trademarks and Customer Relationships, reductions			(34,889)
Finite-Lived Trademarks and Customer Relationships, effects of foreign currency exchange rate			(383)
Finite-Lived Trademarks and Customer Relationships, ending balance	406,042		406,042
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-Lived Trademarks and Customer Relationships, accumulated amortization, beginning balance			150,701
Accumulated amortization, additions			16,548
Accumulated amortization, reductions			(16,136)
Accumulated amortization, effects of foreign exchange rates			(76)
Finite-Lived Trademarks and Customer Relationships, accumulated amortization, ending balance	151,037		151,037
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived, net	255,005		255,005
Indefinite-Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-Lived Trademarks, beginning balance			2,490,303
Indefinite-Lived Trademarks, reductions			(30,562)
Indefinite Lived Trademarks, effects of foreign currency exchange rate			(6,921)
Indefinite-Lived Trademarks, ending balance	$ 2,452,820		$ 2,452,820

Intangible Assets, net (Narrative) (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jul. 02, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Schedule of Intangible Assets [Line Items]
Amortization expense		$ 5,300	$ 5,800	$ 16,548	$ 17,500
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of the year		5,400		5,400
2020		21,500		21,500
2021		21,000		21,000
2022		20,600		20,600
2023		20,600		20,600
2024		$ 20,600		$ 20,600
Trademarks \| Household Cleaning
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles, written off related to sale	$ (18,800)
Indefinite-Lived Trademarks \| Household Cleaning
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangibles, written off related to sale	$ (30,500)

Other Accrued Liabilities (Summary of Accrued Liabilities and Accounts Payable) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Apr. 01, 2018	Mar. 31, 2018
Payables and Accruals [Abstract]
Accrued marketing costs	$ 31,084		$ 21,473
Accrued compensation costs	8,844		10,591
Accrued broker commissions	2,009		1,487
Income taxes payable	6,218		1,901
Accrued professional fees	1,820		2,244
Accrued production costs	5,503		7,392
Other accrued liabilities	10,704		7,013
Total other accrued liabilities	$ 66,182	$ 54,027	$ 52,101

Long-Term Debt (Narrative) (Details) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Debt Instrument [Line Items]
Line of credit facility, amount outstanding	$ 1,842,288,000	$ 1,992,952,000
2016 Senior Notes \| Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	6.375%
2013 Senior Notes \| Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	5.375%
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Line of credit facility, amount outstanding	$ 75,000,000
Line of credit facility, additional borrowing capacity	$ 89,600,000.0

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2018	Mar. 31, 2018
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 1,858,000	$ 2,013,000
Less: unamortized debt costs	(15,712)	(20,048)
Long-term debt, net	1,842,288	1,992,952
2012 ABL Revolver \| Revolving Credit Facility
Debt Instrument [Line Items]
Total long-term debt (including current portion)	75,000	75,000
Long-term debt, net	$ 75,000
Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	6.375%
Total long-term debt (including current portion)	$ 600,000	600,000
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	5.375%
Total long-term debt (including current portion)	$ 400,000	400,000
Term B-5 Loans \| 2012 Senior Notes
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 783,000	$ 938,000
Term B-5 Loans \| 2012 Senior Notes \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)	2.00%
Debt instrument, variable rate, minimum (as percent)	0.00%
Term B-5 Loans \| 2012 Senior Notes \| Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)	1.00%
Debt instrument, variable rate, minimum (as percent)	1.00%

Long-Term Debt (Maturities of Long-term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Mar. 31, 2018
Aggregate Future Principal Payments
2019 (remaining three months ending March 31, 2019)	$ 0
2020	0
2021	0
2022	475,000
2023	0
Thereafter	1,383,000
Total long-term debt (including current portion)	$ 1,858,000	$ 2,013,000

Fair Value Measurements (Summary of Carrying Amounts and Estimated Fair Values) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Mar. 31, 2018
Senior Notes \| 2016 Senior Notes \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 600,000	$ 600,000
Senior Notes \| 2013 Senior Notes \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	400,000	400,000
Term Loans \| 2012 Term B-5 Loans \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	783,000	938,000
Revolving Credit Facility \| 2012 ABL Revolver \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	75,000	75,000
Fair Value, Measurements, Recurring \| Senior Notes \| 2016 Senior Notes \| Fair Value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	582,000	610,500
Fair Value, Measurements, Recurring \| Senior Notes \| 2013 Senior Notes \| Fair Value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	391,000	402,000
Fair Value, Measurements, Recurring \| Term Loans \| 2012 Term B-5 Loans \| Fair Value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	749,723	939,173
Fair Value, Measurements, Recurring \| Revolving Credit Facility \| 2012 ABL Revolver \| Fair Value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	$ 75,000	$ 75,000

Stockholders' Equity (Narrative) (Details)	3 Months Ended		9 Months Ended
Stockholders' Equity (Narrative) (Details)	Dec. 31, 2018 vote $ / shares shares	Dec. 31, 2017 shares	Dec. 31, 2018 USD ($) vote $ / shares shares	Dec. 31, 2017 $ / shares shares	Mar. 31, 2018 $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized (in shares) \| shares	250,000,000		250,000,000		250,000,000
Common stock, par value (in USD per share) \| $ / shares	$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares) \| shares	5,000,000		5,000,000		5,000,000
Preferred stock, par value (in USD per share) \| $ / shares	$ 0.01		$ 0.01		$ 0.01
Voting rights, number of votes per common share owned \| vote	1		1
Dividends declared on common stock \| $			$ 0
Stock repurchased during period (in shares) \| shares			1,449,750
Stock acquired, average cost per share (in USD per share) \| $ / shares			$ 34.47
Treasury stock acquired \| $			$ 50,000,000
Restricted Shares
Class of Stock [Line Items]
Stock repurchased during period (in shares) \| shares	0	0	68,939	20,549
Stock acquired, average cost per share (in USD per share) \| $ / shares			$ 33.09	$ 52.33

Accumulated Other Comprehensive Loss (Components of AOCI) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2018	Mar. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	$ 1,233,120,000	$ 1,178,610,000
Reclassification from accumulated other comprehensive loss into earnings	0	0
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	(27,537,000)	(20,398,000)
Unrecognized net gain on pension plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	1,083,000	1,083,000
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	$ (26,454,000)	$ (19,315,000)

Earnings Per Share (Computation of Basis and Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Numerator
Net income	$ 38,167	$ 314,793	$ 103,474	$ 379,257
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	51,881	53,129	52,119	53,089
Dilutive effect of nonvested restricted stock units and options issued to employees and directors (in shares)	321	414	312	442
Denominator for diluted earnings per share (in shares)	52,202	53,543	52,431	53,531
Earnings per Common Share:
Basic earnings per share (in USD per share)	$ 0.74	$ 5.93	$ 1.99	$ 7.14
Diluted earnings per share (in USD per share)	$ 0.73	$ 5.88	$ 1.97	$ 7.08

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Earnings Per Share (Antidilutive Securities) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0.4	0.5	0.5	0.4

Share-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2018	May 07, 2018	May 31, 2014	Jun. 30, 2014	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation, Aggregate Disclosures:
Maximum number of shares per participant, 12 month period (in shares)			1,000,000.0	2,500,000.0
Extension of plan term				10 years
Share-based compensation costs charged against income					$ 1,900	$ 2,200	$ 6,200	$ 6,900
Tax benefit (expense) recognized from share-based compensation expense					300	$ (100)	1,100	1,400
Unrecognized compensation costs related to nonvested awards					$ 7,600		$ 7,600
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition							1 year
Total fair value of vested shares							$ 12,000	6,800
Proceeds from exercise of stock options							2,931	1,466
Tax benefit realized from exercise of stock options							$ 1,300	$ 1,100
Shares available for issuance under the Plan (in shares)					1,800,000		1,800,000
Stock options granted (in shares)							294,500	182,800
Options, Additional Disclosures:
Options granted, weighted-average grant-date fair value (in USD per share)							$ 10.22	$ 21.20
Options exercised, aggregate intrinsic value							$ 800
Performance Shares
Share-based Compensation, Aggregate Disclosures:
Share grants in period (in shares)		103,406
Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Share grants in period (in shares)		100,399					226,400	105,800
Restricted Stock Units (RSUs) \| Employee
Restricted Shares
Award vesting period							3 years
Restricted Stock Units (RSUs) \| Employee \| Maximum
Restricted Shares
Award vesting period							3 years
Restricted Stock Units (RSUs) \| Director
Share-based Compensation, Aggregate Disclosures:
Share grants in period (in shares)	3,779
Restricted Shares
Number of common shares into which each RSU may be converted (in shares)							1
Period following director's term in which RSUs may be settled							6 months
Stock Options
Share-based Compensation, Aggregate Disclosures:
Stock options granted (in shares)		294,484
Stock options granted, exercise price (in USD per share)		$ 29.46
Stock Options \| Minimum
Restricted Shares
Award vesting period							3 years
Stock Options \| Maximum
Restricted Shares
Award vesting period							5 years
Options, Additional Disclosures:
Award exercisability period, from date of grant							10 years
Long-term Equity Incentive Plan, 2005
Share-based Compensation, Aggregate Disclosures:
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan (in shares)			5,000,000.0
Number of additional shares authorized (in shares)				1,800,000.0

Share-Based Compensation (Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) - $ / shares		9 Months Ended
	May 07, 2018	Dec. 31, 2018	Dec. 31, 2017
Shares
Outstanding, beginning of period (in shares)		393,500	350,100
Granted (in shares)	100,399	226,400	105,800
Vested and issued (in shares)		(175,800)	(53,300)
Forfeited (in shares)		(31,100)	(8,800)
Outstanding, end of period (in shares)		413,000	393,800
Vested, end of period (in shares)		113,200	90,500
Weighted Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)		$ 44.13	$ 39.29
Granted, weighted-average grant-date fair value (in USD per share)		30.09	55.61
Vested and issued, weighted-average grant-date fair value (in USD per share)		43.05	34.30
Forfeited, weighted-average grant-date fair value (in USD per share)		48.32	48.49
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)		36.58	44.14
Vested, end of period, weighted-average grant-date fair value (in USD per share)		$ 31.05	$ 29.88

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($)	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	29.60%	35.20%
Expected dividends	$ 0	$ 0
Expected term in years	6 years	6 years
Risk-free rate	2.90%	2.20%

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Shares
Outstanding, beginning of period (in shares)	873,200	772,300
Granted (in shares)	294,500	182,800
Exercised (in shares)	(97,700)	(51,000)
Forfeited or expired (in shares)	(125,400)	(22,100)
Outstanding, end of period (in shares)	944,600	882,000
Exercisable, end of period (in shares)	499,400	502,900
Weighted Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 41.79	$ 37.70
Granted, weighted-average exercise price (in USD per share)	29.46	56.11
Exercised, weighted-average exercise price (in USD per share)	30.02	28.76
Forfeited or expired, weighted-average exercise price (in USD per share)	47.16	48.15
Outstanding, end of period, weighted-average exercise price (in USD per share)	38.45	41.77
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 37.87	$ 32.50
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	7 years 2 months	7 years 2 months
Exercisable, end of period, weighted-average remaining contractual term	5 years 9 months 18 days	6 years 1 month
Outstanding, end of period, aggregate intrinsic value	$ 2,477	$ 7,019
Exercisable, end of period, aggregate intrinsic value	$ 2,076	$ 6,884

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Net gain related to value of deferred tax liabilities					$ 267.0
Net gain related to lower blended rate					3.2
Net gain					270.2
Tax Cuts and Jobs Act of 2017, incomplete accounting, transition tax for foreign earnings, provisional income tax expense					1.9
Effective income tax rate (percent)	25.20%	(446.10%)	26.60%	(137.60%)
Uncertain tax liability	$ 9.8		$ 9.8		$ 10.8

Employee Retirement Plans (Expected Return on Plan Assets) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Interest cost	$ 599	$ 631	$ 1,819	$ 1,894
Expected return on assets	(767)	(725)	(2,303)	(2,176)
Net periodic benefit income	$ (168)	$ (94)	$ (484)	$ (282)

Employee Retirement Plans (Narrative) (Details)	9 Months Ended
Employee Retirement Plans (Narrative) (Details)	Dec. 31, 2018 USD ($)
Non-qualified Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contributions	$ 300,000
Expected employer contributions, remainder of fiscal year	100,000
Qualified Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contributions	1,000,000
Expected employer contributions, remainder of fiscal year	$ 0

Concentrations of Risk (Narrative) (Details) - manufacturer	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Concentration Risk [Line Items]
Number of third-party manufacturers	112	114	112	114
Sales \| Customer Concentration Risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage (percent)	22.30%	21.40%	23.50%	24.00%
Sales \| Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (percent)			60.40%	74.20%
Number of third-party manufacturers with long-term contracts			33	46
Top 5 brands \| Sales \| Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (percent)	41.70%	39.90%	42.80%	41.20%

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information, Profit (Loss):
Total revenues	$ 241,414	$ 270,615	$ 734,751	$ 785,214
Cost of sales	102,179	122,941	317,421	349,966
Gross profit	139,235	147,674	417,330	435,248
Advertising and promotion	34,504	35,835	108,657	111,967
Contribution margin	104,731	111,839	308,673	323,281
Other operating expenses	27,190	27,949	87,721	84,711
Operating income	77,541	83,890	220,952	238,570
Other expense	26,545	26,251	79,977	78,922
Income before income taxes	50,996	57,639	140,975	159,648
Provision (benefit) for income taxes	12,829	(257,154)	37,501	(219,609)
Net income	38,167	314,793	103,474	379,257
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	216,776	225,695	647,501	656,812
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	24,638	25,717	67,439	67,572
Household Cleaning
Segment Reporting Information, Profit (Loss):
Total revenues	0	19,203	19,811	60,830
Operating Segments \| North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	216,776	225,695	647,501	656,812
Cost of sales	91,594	95,164	272,754	268,849
Gross profit	125,182	130,531	374,747	387,963
Advertising and promotion	30,316	30,794	96,899	98,666
Contribution margin	94,866	99,737	277,848	289,297
Operating Segments \| International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	24,638	25,717	67,439	67,572
Cost of sales	10,585	10,511	28,079	29,757
Gross profit	14,053	15,206	39,360	37,815
Advertising and promotion	4,188	4,544	11,328	11,827
Contribution margin	9,865	10,662	28,032	25,988
Operating Segments \| Household Cleaning
Segment Reporting Information, Profit (Loss):
Total revenues	0	19,203	19,811	60,830
Cost of sales	0	17,266	16,588	51,360
Gross profit	0	1,937	3,223	9,470
Advertising and promotion	0	497	430	1,474
Contribution margin	0	1,440	2,793	7,996
Intersegment Eliminations \| North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	$ (1,300)	$ (1,900)	$ (5,600)	$ (5,600)

Business Segments (Revenue) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 241,414	$ 270,615	$ 734,751	$ 785,214
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	29,461	31,453	86,639	90,640
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	31,721	33,092	79,332	81,341
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	64,252	66,047	194,870	196,128
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	41,058	40,643	118,326	113,268
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	26,516	24,836	82,447	78,287
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	21,978	23,298	73,575	74,275
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	24,833	30,411	75,566	86,282
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,595	1,632	4,185	4,163
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	19,203	19,811	60,830
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	216,776	225,695	647,501	656,812
North American OTC Healthcare \| Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	29,325	31,293	86,221	89,931
North American OTC Healthcare \| Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	27,137	28,761	63,843	67,738
North American OTC Healthcare \| Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	60,946	63,107	186,037	187,688
North American OTC Healthcare \| Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	30,737	29,392	94,065	88,145
North American OTC Healthcare \| Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	23,352	21,631	73,669	69,437
North American OTC Healthcare \| Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	21,508	22,736	71,968	72,688
North American OTC Healthcare \| Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	22,177	27,144	67,516	77,026
North American OTC Healthcare \| Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,594	1,631	4,182	4,159
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	24,638	25,717	67,439	67,572
International OTC Healthcare \| Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	136	160	418	709
International OTC Healthcare \| Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	4,584	4,331	15,489	13,603
International OTC Healthcare \| Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,306	2,940	8,833	8,440
International OTC Healthcare \| Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	10,321	11,251	24,261	25,123
International OTC Healthcare \| Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,164	3,205	8,778	8,850
International OTC Healthcare \| Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	470	562	1,607	1,587
International OTC Healthcare \| Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,656	3,267	8,050	9,256
International OTC Healthcare \| Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1	1	3	4
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	19,203	19,811	60,830
Household Cleaning \| Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning \| Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning \| Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning \| Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning \| Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning \| Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning \| Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning \| Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning \| Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 0	$ 19,203	$ 19,811	$ 60,830

Business Segments (Revenue by Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 241,414	$ 270,615	$ 734,751	$ 785,214
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	204,943	232,583	632,183	682,928
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 36,471	$ 38,032	$ 102,568	$ 102,286

Business Segments (Goodwill and Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Mar. 31, 2018
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 611,956	$ 620,098
Intangible assets
Indefinite-lived	2,452,820	2,490,303
Finite-lived, net	255,005	290,613
Intangible assets, net	2,707,825	2,780,916
Total	3,319,781	3,401,014
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	580,934	580,934
Intangible assets
Indefinite-lived	2,375,735	2,375,736
Finite-lived, net	249,637	265,356
Intangible assets, net	2,625,372	2,641,092
Total	3,206,306	3,222,026
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	31,022	32,919
Intangible assets
Indefinite-lived	77,085	84,006
Finite-lived, net	5,368	6,068
Intangible assets, net	82,453	90,074
Total	113,475	122,993
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	0	6,245
Intangible assets
Indefinite-lived	0	30,561
Finite-lived, net	0	19,189
Intangible assets, net	0	49,750
Total	$ 0	$ 55,995